The Philly innovation pipeline is creating dozens smaller startups that are rising through the ranks, representing the future of an already vibrant Philadelphia biomed innovation cluster – which has the potential to be one of the top hubs in the world.
Using its powerful artificial intelligence-driven Concentriq digital pathology platform, Proscia is accelerating breakthroughs in precision medicine. David West, Co-Founder and Chief Executive Officer of Proscia, explained that pathology has been a core component of research and diagnosis for more than 150 years. But, with advances in technology and machine learning capabilities, the field is shifting away from microscopes and glass slides and becoming a data-driven discipline that is more reliant on the use of high-resolution digital imagery.
Philadelphia medical technology company Proscia raised a $37 million Series C funding round, doubling what it has taken in from investors since its inception eight years ago.
Founded in 2014 by a team of biomedical engineers from Johns Hopkins University and the University of Pittsburgh, the company uses artificial intelligence to improve how pathologists diagnose cancer.